Optimizing Care for Patients with Relapsed/Refractory Multiple Myeloma
| Title: | Optimizing Care for Patients with Relapsed/Refractory Multiple Myeloma |
| Topic: | Oncology/ Hematology |
| Relevant Terms: | Cancer, Multiple Myeloma |
| Primary Audience: | Hematologists; Oncologists; Oncology Pharmacists |
| Launch Date: | 09-Nov-12 |
| Credits: | 1 AMA PRA Category 1 Credit™ 1 ACPE contact hour |
| Expiration Date: | 08-Nov-13 |
| Patients Seen: |   |
| Curriculum Name: | Optimizing Care for Patients with Relapsed/Refractory Multiple Myeloma |
Learning Objectives
After completing this activity, the participant will demonstrate the ability to:
- Assess outcomes for patients with relapsed/refractory multiple myeloma
- Evaluate the biological role of therapies in development for multiple myeloma
- Compare and contrast efficacy and safety data for novel agents in the treatment of relapsed/refractory multiple myeloma
- Formulate an appropriate, individualized treatment approach when given relapsed/refractory multiple myeloma case scenarios designed to achieve optimal patient outcomes
- Evaluate patients with relapsed/refractory multiple myeloma suitable for enrollment in ongoing clinical trials
Faculty
Martha Q. Lacy, MD
Professor of Medicine
Division of Hematology
Mayo Clinic College of Medicine
Rochester, Minnesota
Elizabeth Bilotti, MSN, RN, APN
John Theurer Cancer Center
Hackensack University Medical Center
Hackensack, New Jersey
Katherine Sanvidge Shah, PharmD, BCOP
Hematology/Oncology Pharmacy Specialist
Emory University Hospital
Winship Cancer Institute
Atlanta, Georgia
Thomas G. Martin III, MD
Clinical Professor of Medicine
Multiple Myeloma Translational Initiative
UCSF Medical Center
University of California, San Francisco
San Francisco, California
Professor of Medicine
Division of Hematology
Mayo Clinic College of Medicine
Rochester, Minnesota
Elizabeth Bilotti, MSN, RN, APNJohn Theurer Cancer Center
Hackensack University Medical Center
Hackensack, New Jersey
Katherine Sanvidge Shah, PharmD, BCOPHematology/Oncology Pharmacy Specialist
Emory University Hospital
Winship Cancer Institute
Atlanta, Georgia
Thomas G. Martin III, MDClinical Professor of Medicine
Multiple Myeloma Translational Initiative
UCSF Medical Center
University of California, San Francisco
San Francisco, California
Estimated time to complete activity: 1 hour
Release date: Friday, November 9, 2012 | Expiration date: Friday, November 8, 2013
TARGET AUDIENCE
The target audience for this activity is medical oncologists, hematologist-oncologists, oncology pharmacists, and oncology nurses caring for patients with relapsed/refractory multiple myeloma.
DESIGNATION OF CREDIT
PHYSICIAN CONTINUING EDUCATION
Accreditation Statement
Educational Concepts Group, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement
Educational Concepts Group, LLC designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Accreditation Statement
Educational Concepts Group, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement
Educational Concepts Group, LLC designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
PHARMACIST CONTINUING EDUCATION
Educational Concepts Group, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Educational Concepts Group, LLC designates this continuing education activity for 1.0 contact hour (0.10 CEU) (UAN 0199-0000-12-038-H01-P).
Educational Concepts Group, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Educational Concepts Group, LLC designates this continuing education activity for 1.0 contact hour (0.10 CEU) (UAN 0199-0000-12-038-H01-P).
Type of activity: Application-based
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME/CE credit for this activity. During the period Friday, November 9, 2012 through Friday, November 8, 2013, participants must 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the post-activity assessment.
There are no fees for participating and receiving CME/CE credit for this activity. During the period Friday, November 9, 2012 through Friday, November 8, 2013, participants must 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the post-activity assessment.
CME/CE CREDIT
Physicians and pharmacists who complete the post-activity assessment with a score of 70% or better may view and print their credit letter or statement of credit via the website, www.educationalconcepts.net.
Physicians and pharmacists who complete the post-activity assessment with a score of 70% or better may view and print their credit letter or statement of credit via the website, www.educationalconcepts.net.
POLICY ON DISCLOSURE
It is the policy of ECG that the faculty, authors, planners, and other persons who may influence content of this CME/CE activity disclose all relevant financial relationships with commercial interests in order to allow ECG to identify and resolve any potential conflicts of interest.
The Following Faculty Members Have Declared Relevant Financial Relationships
Elizabeth Bilotti, MSN, RN, APN
Grants/Research Support, Consultant Fees, Honorarium
Celgene Corporation, Millennium: The Takeda Oncology Company
Martha Q. Lacy, MD
Grants/Research Support
Celgene Corporation
Thomas G. Martin III, MD
Grants/Research Support
Celgene Corporation
Consultant Fees
Novartis
Speakers' Bureau
Celgene Corporation, Novartis
Katherine Sanvidge Shah, PharmD, BCOP
Honorarium
Millennium: The Takeda Oncology Company
Staff Disclosure
Planners and managers at ECG have no relevant financial relationships to disclose.
DISCLOSURE OF OFF-LABEL USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. ECG does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity do not necessarily represent the views of ECG. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. ECG does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity do not necessarily represent the views of ECG. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Please refer to the official prescribing information for each product or consult the Physicians' Desk Reference for discussion of approved indications, contraindications, and warnings.
ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT
This activity is supported by an educational grant from Onyx Pharmaceuticals, Inc.
ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT
This activity is supported by an educational grant from Onyx Pharmaceuticals, Inc.
CME/CE INQUIRIES
For further information, please contact:
Educational Concepts Group, LLC
1300 Parkwood Circle SE, Suite 325
Atlanta, Georgia 30339
Phone: 1.866.933.1681
Fax: 1.866.933.1692
www.educationalconcepts.net
This activity is sponsored by Educational Concepts Group, LLC
This activity is supported by an educational grant from Onyx Pharmaceuticals, Inc.
